Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes.

Oncotarget - 14 Mar 2017

Liao Wen-Ling, Lee Wen-Jane, Chen Ching-Chu, Lu Chieh Hsiang, Chen Chien-Hsiun, Chou Yi-Chun, Lee I-Te, Sheu Wayne H-H, Wu Jer-Yuarn, Yang Chi-Fan, Wang Chung-Hsing, Tsai Fuu-Jen

Abstract excerpt

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors' advantages, the patients' therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Drug Resistance

Share to Hypoglycemic Agents

Share to Pharmacogenomic Testing

Share to Protein Kinase C

Share to Taiwan

Source

Open in PubMed Open full text

Identifiers

PMID: 28160554
DOI: 10.18632/oncotarget.14951
PMCID: PMC5392306

Genes

PRKD1
CNTN3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes.PMID 28160554Read ↗

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan.Semantic proximity Read ↗

Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity Read ↗

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity Read ↗

Pharmacogenomic Profiling of Selected Genes Influencing Anti-Diabetic Drug Response in the Pakistani Pashtun Population: Shifting from Trial-and-Error to Precision MedicineSemantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.Semantic proximity Read ↗

Pharmacogenetics of metformin response: a step in the path toward personalized medicine.Semantic proximity Read ↗

Pharmacogenetics of Type 2 Diabetes—Progress and ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.